Tarrytown-based Regeneron anticipates adding 230 new jobs within three years of competing construction to transform the former Avon Products site at...
Regeneron sued Viatris’ Mylan unit, claiming that its proposed biosimilar copy of Eylea infringed 24 of its patents.
From 2014 to 2019, Rabinowitz and Samber allegedly obtained cheaper products by telling manufacturers that the products would be sold outside...
White Plains Hospital has launched a new heart program that includes offering an advanced heart aortic valve replacement procedure. The hospital...
Desmoid tumors are locally aggressive and invasive soft-tissue tumors that can be life-threatening.
Stamford-based Cara will receive an initial payment of $17.5 million from HCRx, also in Stamford.
MNKD-101 has been designated by the FDA as both an orphan drug and a qualified infectious disease product.
LifeSpan's Harry Robb said the investment is part of the firm's goal "to advance the longevity field."
Hassan is the former chairman of the board and CEO of Schering-Plough Corp.
The companies will initially research two in vivo non-liver targets.
Under the terms of the agreement, Regeneron has the right to develop and commercialize therapeutic antibodies resulting from the collaboration.
A hitherto unpublicized clause details the pricing of a potential commercialized therapy.
He joins the Stamford-based company from Black Diamond Therapeutics.
U.S. Rep. Marc Molinaro hosted a forum Sept. 5 at the Monticello Fire House on mental health and substance use disorders....
"We have long admired the exceptional scientific legacy at Regeneron," said Dr. Robert J. Hariri, Celularity’s CEO.